A comprehensive comparison of the incidence of adverse events in large cohorts of paediatric CKD patients with and without GH treatment revealed no significant association between GH therapy and the incidence of malignancy, slipped capital femoral epiphysis, avascular necrosis, glucose intolerance, pancreatitis, rapid progression of CKD, acute allograft rejection or fluid retention91. Here, GH1 is linked to Glucose intolerance.